Building the future therapies for Down syndrome: the third international conference of the T21 research society

Dierssen, Mara; Martínez de Lagrán Cabredo, María; Vazquez, Anna; Bhattacharyya, Anita

doi:http://dx.doi.org/10.1159/000514437

Building the future therapies for Down syndrome: the third international conference of the T21 research society

Citation

Dierssen M, Herault Y, Helguera P, Martínez de Lagran M, Vazquez A, Christian B et al. Building the future therapies for Down syndrome: the third international conference of the T21 research society. Mol Syndromol. 2021;12(4):202-18. DOI: 10.1159/000514437

Abstract

Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.